In discussions about contraceptives, it has historically only fallen on women. To some extent, it is understandable that women, when assuming a great responsibility, decide which direction is right for them. Should an encounter "bear fruit", much of the thinking about contraceptives has evolved in recent years and men are more responsible. Now, a new study collaboration from researchers at UNC-Chapel Hill, Oregon Health and Natural Sciences University (OHSU), and Eppin Pharma details how a compound called EP055 binds to sperm proteins to significantly slow overall sperm motility without to influence the hormones EP055 a possible "male pill" without side effects.
Results of the new study were recently published in PLOS ONE by an article entitled "Inhibition of sperm motility in male macaques with EP055, a potential non-hormonal male contraceptive."
"Put simply," the compound disables sperm's ability to swim, which significantly limits fertilization capabilities, "said Michael O. Rand, Ph.D., president / CEO of Eppin Pharma and professor of cell biology and physiology Retired at the University of North Carolina at the Chapel Hill School of Medicine, and. "This makes EP055 an ideal candidate for non-hormonal male prevention."
Currently, condoms and surgical vasectomies are the only safe forms of Birth control currently available to men, but there are hormonal drugs in clinical trials aimed at producing sperm, but these affect natural hormones in men as well as female contraceptives that affect women's hormones.
In the current The researchers showed that there was no evidence of normal sperm motility 30 hours after a high-dose intravenous infusion of EP055 in male rhesus macaques. In addition, no physical side effects were observed.
"One particular target is the sperm epididymal protease inhibitor (EPPIN) present on the surface of human spermatozoa," the authors write. "EP055 is a small organic compound that targets EPPIN on the surface of sperm and inhibits motility EP055 was tested in males by Cynomolgus ( Macaca fascicularis ) to determine its plasma half-life after intravenous (IV) infusion
"Our first study demonstrated a plasma half-life for EP055 of 1
Surprisingly, the researchers showed that the monkeys showed no signs of side effects and their physiology returned to their normal state.
"Eighteen days after the infusion, all macaques showed signs of complete recovery, suggesting that the compound EP055 is actually reversible, "said researcher Mary Zelinski, a research associate at ONPRC, at the OHSU and associate professor of obstetrics and gynecology at the OHSU School of Medicine.
The scientists emphasized that more work is needed before EP055 for is available to human use and that they have begun to test a pill form of the compound – finally a mating trial of the efficacy of EP055 against pregnancy.